Nurix Therapeutics Inc at UBS Virtual Targeted Protein Degradation Day Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: David Dai - UBS Equities - Analyst : Yeah. Sure. Sounds good, Arthur. Maybe before we dive in, just help us understand what are some of the key updates we should be expecting over the next 12 months?

Question: David Dai - UBS Equities - Analyst : That's excellent. Let's -- so talk about the lead program, 5948, your BTK degrader targeting multiple myeloma and lymphoma. So you recently presented some data at the EHA this year. Can you just walk us through the summary of the key data points and where you are currently with this program?

Question: David Dai - UBS Equities - Analyst : Yeah, that's excellent. I apologize. I misspoke on the indication, it should CLL, not auto myeloma-- my apologies.

Question: David Dai - UBS Equities - Analyst : On that front, there looks about 70% ORR, looks very interesting. Maybe just help us understand what will be considered reasonable benchmark for this particular line of CLL patients?

Question: David Dai - UBS Equities - Analyst : Got it. That's really helpful. And so then just on the CNS front, you've seen some quite interesting data, especially from that case study where one patient had some CNS benefits. Could you maybe just elaborate on the CNS penetration activities for your drug?

Question: David Dai - UBS Equities - Analyst : Got it. So could this be considered one of the key differentiator of this drug versus other BTK inhibitors?

Question: David Dai - UBS Equities - Analyst : Got it. And that's really helpful. And then just on the next phase, which is going to be your development plan for monotherapy and combo pivotal trials. Any thoughts on your trial design and what's the regulatory path so far? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JULY 15, 2024 / 6:30PM, NRIX.OQ - Nurix Therapeutics Inc at UBS Virtual Targeted Protein Degradation Day

Question: David Dai - UBS Equities - Analyst : Got it. That's really interesting. So on the -- moving on to the lymphoma opportunity, so we should be seeing some additional data in NHL patients in the second half of this year. Could you perhaps just set some expectations for data readout? Or what would be sort of like consider clinically meaningful benchmark, which should be expected here?

Question: David Dai - UBS Equities - Analyst : Got it. Helpful. And so then talk a little more about the autoimmune disease for 5948. I know you're actually planning to go into the autoimmune for this BTK as well. So any initial thoughts around indication you're going to be pursuing for 5948 in the autoimmune disease?

Question: David Dai - UBS Equities - Analyst : Got it. And so right now, you're in IND-enabling stage right now. Was it fair to say that probably -- potentially moving into clinics some time in 2025 for this program for autoimmune.

Question: David Dai - UBS Equities - Analyst : Got it. That's really helpful. And so let's move on to the second program, which is your 2127, the BTK-IKZF dual degrader program. Maybe just to start things off, just walk us through some of the potential synergy of targeting both BTK and IKZF. And how do you think that would lead to potentially a deeper and durable response in lymphoma?

Question: David Dai - UBS Equities - Analyst : Excellent. So maybe just set some benchmark again, Arthur, if you don't mind. So I know you're going after DLBCL, especially relapsed/refractory setting with multiple prior lines. And so in this population, I would imagine these are very sick patients. So how should we think about the benchmark in this setting? What's sort of like the bar which we're looking at here?

Question: David Dai - UBS Equities - Analyst : Got it. That's helpful. And then just on the -- stay on the topic around your commercial product. So recently, you resolved the partial clinical hold of 2127. Can you just talk more about for investors who are new to the story. Mind us what was the kind of the reason behind the partial clinical hold. And then -- and what was being resolved so far?

Question: David Dai - UBS Equities - Analyst : Excellent. All right. So now we have about three or four minutes left here. I want to quickly introduce the next program for IO, which is your 1607 program. Maybe just a quick overview of the CBL-B program, and then we should be expecting some data update later this year, as you said, Arthur. So maybe set some expectations around what should we be looking for in the update?

Question: David Dai - UBS Equities - Analyst : Got it. And lastly, just on the collaboration with Gilead and Sanofi for the two I&I programs, IRAK4 and STAT6 programs, which are getting a lot of attention nowadays. So maybe just quickly walk us through the programs, where you are currently with these two programs, and what are the milestones you be expecting over the next, say, 12, 24 months?

Question: David Dai - UBS Equities - Analyst : Excellent. Just one last question on the financials. Maybe just help us understand your cash position, your cash runway.

Question: David Dai - UBS Equities - Analyst : Excellent. With that, we're at the top of the hour. I want to thank you, Arthur, for taking this time to walk us through the Nurix story. Thank you so much, Arthur.